Bringing TPG’s scale and expertise to drive Innovation in life sciences
TPG’s Life Sciences Innovation (LSI) fund will invest in novel therapeutics as well as digital health, medical devices, diagnostics, and tech-enabled services, leveraging our core team’s and TPG’s broad expertise in healthcare to focus on supporting companies that are meaningfully improving patients’ outcomes. LSI will invest across therapeutic areas and stages from company creation to IPO. We pride ourselves on being great partners, with a differentiated ability to scale our investment based on companies’ needs.
Built on a track record of successfully investing in and supporting cutting-edge life science companies
LSI builds on TPG’s history of successful healthcare investing, including $750 million invested in life sciences in the last three years and $7.6 billion invested in healthcare over the last 10 years.
LSI has deep scientific and clinical domain expertise embedded within a market-leading healthcare investment franchise. The team is able to provide customized expertise from an extended network of TPG advisors to support the growth of our portfolio companies. As the pace of research, development, and innovation in the life sciences sector accelerates, LSI is well positioned to support the growth of young companies, from company creation through pre-clinical and clinical development to commercial stages.